JP2023524504A5 - - Google Patents
Info
- Publication number
- JP2023524504A5 JP2023524504A5 JP2022566358A JP2022566358A JP2023524504A5 JP 2023524504 A5 JP2023524504 A5 JP 2023524504A5 JP 2022566358 A JP2022566358 A JP 2022566358A JP 2022566358 A JP2022566358 A JP 2022566358A JP 2023524504 A5 JP2023524504 A5 JP 2023524504A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- halogen
- aldose reductase
- formula
- reductase inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025180336A JP2026012262A (ja) | 2020-05-01 | 2025-10-27 | ソルビトールデヒドロゲナーゼ欠乏症を処置するためのアルドースレダクターゼ阻害剤 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063019186P | 2020-05-01 | 2020-05-01 | |
| US63/019,186 | 2020-05-01 | ||
| US202063019738P | 2020-05-04 | 2020-05-04 | |
| US63/019,738 | 2020-05-04 | ||
| PCT/US2021/029286 WO2021222165A1 (en) | 2020-05-01 | 2021-04-27 | Aldose reductase inhibitors for treating sorbitol dehydrogenase deficiency |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025180336A Division JP2026012262A (ja) | 2020-05-01 | 2025-10-27 | ソルビトールデヒドロゲナーゼ欠乏症を処置するためのアルドースレダクターゼ阻害剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023524504A JP2023524504A (ja) | 2023-06-12 |
| JP2023524504A5 true JP2023524504A5 (enExample) | 2024-05-10 |
| JP7788399B2 JP7788399B2 (ja) | 2025-12-18 |
Family
ID=75954272
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022566358A Active JP7788399B2 (ja) | 2020-05-01 | 2021-04-27 | ソルビトールデヒドロゲナーゼ欠乏症を処置するためのアルドースレダクターゼ阻害剤 |
| JP2025180336A Pending JP2026012262A (ja) | 2020-05-01 | 2025-10-27 | ソルビトールデヒドロゲナーゼ欠乏症を処置するためのアルドースレダクターゼ阻害剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025180336A Pending JP2026012262A (ja) | 2020-05-01 | 2025-10-27 | ソルビトールデヒドロゲナーゼ欠乏症を処置するためのアルドースレダクターゼ阻害剤 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20230121312A1 (enExample) |
| EP (1) | EP4135674A1 (enExample) |
| JP (2) | JP7788399B2 (enExample) |
| KR (1) | KR20230005944A (enExample) |
| CN (1) | CN115996725A (enExample) |
| AU (1) | AU2021264454A1 (enExample) |
| BR (1) | BR112022021845A2 (enExample) |
| CA (1) | CA3176768A1 (enExample) |
| IL (1) | IL297779A (enExample) |
| MX (1) | MX2022013658A (enExample) |
| WO (1) | WO2021222165A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL272246B2 (en) | 2017-07-28 | 2026-01-01 | Applied Therapeutics Inc | History of 2-(4-oxo/thioketone/azo-3-((substituted)benzo[d]thiazol-2-yl)methyl)- 3,4-dihydrothieno[3,4-d]pyridazin-1-yl)acetic acid for use as an aldose reductase inhibitor for the treatment of galactosemia or prevention of galactosemia-related complications |
| CN113840825A (zh) | 2019-04-01 | 2021-12-24 | 应用治疗公司 | 醛糖还原酶抑制剂 |
| MX2021013511A (es) | 2019-05-07 | 2022-02-23 | Univ Miami | Tratamiento y deteccion de neuropatias heredadas y trastornos asociados. |
| GB202400033D0 (en) | 2024-01-02 | 2024-02-14 | Nicolnson Tamara | Therapy i |
| WO2025219948A1 (en) * | 2024-04-17 | 2025-10-23 | Assia Chemical Industries Ltd. | Crystalline forms of govorestat |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4939140A (en) | 1985-11-07 | 1990-07-03 | Pfizer Inc. | Heterocyclic oxophthalazinyl acetic acids |
| JPH0495025A (ja) | 1990-08-08 | 1992-03-27 | Asahi Chem Ind Co Ltd | アルドースリダクターゼ阻害剤 |
| US5464961A (en) | 1993-09-10 | 1995-11-07 | Olin Corporation | Arcjet anode |
| US5624949A (en) | 1993-12-07 | 1997-04-29 | Eli Lilly And Company | Protein kinase C inhibitors |
| CN1200106A (zh) | 1995-08-28 | 1998-11-25 | 美国家用产品公司 | 苯氧基乙酸类化合物用作醛糖还原酶抑制剂和抗高血糖药 |
| PL179170B1 (pl) | 1995-09-15 | 2000-07-31 | Inst Lekow | Nowe zwiazki,pochodne genisteiny PL PL PL PL |
| ES2122764T3 (es) | 1995-11-20 | 1998-12-16 | Lilly Co Eli | Inhibidor de la proteina quinasa c. |
| AU6473898A (en) * | 1997-03-21 | 1998-10-20 | Regents Of The University Of California, The | Methods for modulating neurotrophic factor-associated activity using aldose reductase inhibitors |
| GB9714274D0 (en) * | 1997-07-08 | 1997-09-10 | Zeneca Ltd | Pharmaceutical composition |
| EP0982306A3 (en) | 1998-08-21 | 2000-07-05 | Pfizer Products Inc. | Polymorph of zopolrestat monohydrate |
| US6570013B2 (en) | 2000-02-16 | 2003-05-27 | Pfizer Inc | Salts of zopolrestat |
| WO2003105864A1 (en) | 2002-06-13 | 2003-12-24 | Board Of Regents, The University Of Texas System | Methods and compositions involving aldose reductase inhibitors |
| EP2065038A1 (en) * | 2007-11-30 | 2009-06-03 | Pharnext | New therapeutic approaches for treating Charcot-Marie-Tooth disease |
| HUE031506T2 (en) | 2010-07-16 | 2017-07-28 | Univ Columbia | Aldose reductase inhibitors and their use |
| US8916563B2 (en) | 2010-07-16 | 2014-12-23 | The Trustees Of Columbia University In The City Of New York | Aldose reductase inhibitors and uses thereof |
| JP6500992B2 (ja) | 2015-09-01 | 2019-04-17 | 株式会社村田製作所 | コイル内蔵部品 |
| ES2966094T3 (es) | 2016-06-21 | 2024-04-18 | Univ Columbia | Compuestos 4-oxo-3,4-dihidrotieno[3,4-d]piridazina como inhibidores de la aldosa reductasa y métodos de uso de los mismos |
| IL272246B2 (en) | 2017-07-28 | 2026-01-01 | Applied Therapeutics Inc | History of 2-(4-oxo/thioketone/azo-3-((substituted)benzo[d]thiazol-2-yl)methyl)- 3,4-dihydrothieno[3,4-d]pyridazin-1-yl)acetic acid for use as an aldose reductase inhibitor for the treatment of galactosemia or prevention of galactosemia-related complications |
-
2021
- 2021-04-27 KR KR1020227042040A patent/KR20230005944A/ko active Pending
- 2021-04-27 BR BR112022021845A patent/BR112022021845A2/pt unknown
- 2021-04-27 EP EP21726266.6A patent/EP4135674A1/en active Pending
- 2021-04-27 MX MX2022013658A patent/MX2022013658A/es unknown
- 2021-04-27 AU AU2021264454A patent/AU2021264454A1/en active Pending
- 2021-04-27 IL IL297779A patent/IL297779A/en unknown
- 2021-04-27 JP JP2022566358A patent/JP7788399B2/ja active Active
- 2021-04-27 CN CN202180044285.7A patent/CN115996725A/zh active Pending
- 2021-04-27 WO PCT/US2021/029286 patent/WO2021222165A1/en not_active Ceased
- 2021-04-27 CA CA3176768A patent/CA3176768A1/en active Pending
-
2022
- 2022-10-28 US US18/050,627 patent/US20230121312A1/en not_active Abandoned
-
2024
- 2024-02-01 US US18/429,719 patent/US20240238288A1/en active Pending
-
2025
- 2025-10-27 JP JP2025180336A patent/JP2026012262A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5389030B2 (ja) | （特に）嚢胞性線維症の処置に有用なイソチアゾロピリジノン | |
| JP2019534291A5 (enExample) | ||
| US20210228564A1 (en) | Pyrvinium pamoate therapies and methods of use | |
| JP2020528938A5 (enExample) | ||
| JP2021529780A5 (enExample) | ||
| JP2021511360A5 (enExample) | ||
| JP7834686B2 (ja) | アポリポタンパク質（ａ）発現の調節 | |
| US20110003013A1 (en) | Method of increasing metabolism | |
| EP3787626B1 (en) | Phosphonamidates that are bcl family antagonists for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer | |
| JP2017520571A (ja) | 様々な疾患の処置のためのｊｎｋシグナル伝達経路の細胞透過性ペプチド阻害剤の新規使用 | |
| US9814741B2 (en) | Methods relating to DNA-sensing pathway related conditions | |
| WO2016200726A1 (en) | Inhibitors of mci-1 as drugs to overcome resistance to braf inhibitors and mek inhibitors | |
| Judd et al. | BCL-XL–targeting antibody-drug conjugates are active in preclinical models and mitigate on-mechanism toxicity of small-molecule inhibitors | |
| JP2022547452A (ja) | Ａｃｔｒｉｉ受容体拮抗薬を含む肝疾患または肝臓障害の治療 | |
| Humphries et al. | Activation of human meningeal cells is modulated by lipopolysaccharide (LPS) and non‐LPS components of Neisseria meningitidis and is independent of Toll‐like receptor (TLR) 4 and TLR2 signalling | |
| CN104159589A (zh) | 肝脏状况的治疗 | |
| AU2010236181B2 (en) | Method of treating hepatocellular carcinoma | |
| JP2021522327A5 (enExample) | ||
| JP2025098099A (ja) | ブルトン型チロシンキナーゼ阻害剤の投薬 | |
| EP3484864A1 (en) | Pyrimidinone derivatives and uses thereof to neutralize the biological activity of chemokines | |
| TWI810397B (zh) | 治療癌症之方法 | |
| JP6368363B2 (ja) | デングウィルス特異的ｓｉＲＮＡ、そのようなｓｉＲＮＡを含む二重らせんオリゴＲＮＡ構造体およびこれを含むデングウィルス増殖抑制用組成物 | |
| JP7493460B2 (ja) | 有機化合物 | |
| Wang et al. | Novel Hsp90α inhibitor inhibits HSV-1 infection by suppressing the Akt/β-catenin pathway | |
| Zhao et al. | Atherogenesis in the carotid artery with and without interrupted blood flow of two hyperlipidemic mouse strains |